Apixiban for VTE reduced subsequent hospitalizations

WASHINGTON – Treating acute venous thromboembolism with the fixed-dose oral factor Xa inhibitor apixaban significantly reduces subsequent all-cause hospitalizations, compared with conventional...

Field of Interest: Cardiology
Type: News Item

FDA declines to approve IV antiplatelet drug cangrelor

The Food and Drug Administration has rejected the approval of the intravenous antiplatelet drug cangrelor, suggesting that the company provide more data, according to the drug’s manufacturer. The...

Field of Interest: Cardiology
Type: News Item

GERD may boost risk of MI

CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease. In a nationwide case-control study of prodigious proportions,...

Field of Interest: Cardiology
Type: News Item

GERD may boost risk of MI

CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease. In a nationwide case-control study of prodigious proportions,...

Field of Interest: Gastroentero...
Type: News Item

VIDEO: GERD may boost increase heart attack risk

CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease. In a nationwide case-control study of prodigious proportions,...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.